Signalisation PI3K/Akt/mTOR
Les inhibiteurs de la signalisation PI3K/Akt/mTOR sont des composés qui ciblent les voies de la phosphoinositide 3-kinase (PI3K), de la kinase Akt et de la cible de la rapamycine chez les mammifères (mTOR). Ces voies sont des régulateurs critiques de la croissance cellulaire, de la survie, du métabolisme et de l'autophagie, ce qui en fait des cibles clés dans la recherche sur le cancer et les troubles métaboliques. Inhiber ces voies peut aider à contrôler la croissance et la prolifération tumorales, offrant ainsi des stratégies thérapeutiques potentielles pour divers cancers et autres maladies caractérisées par une signalisation cellulaire dysrégulée. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de haute qualité de PI3K/Akt/mTOR pour soutenir vos recherches en oncologie, signalisation cellulaire et maladies métaboliques.
Sous-catégories appartenant à la catégorie "Signalisation PI3K/Akt/mTOR"
- AMPK(170 produits)
- ATM/ATR(72 produits)
- ADN-PK(49 produits)
- EGFR(581 produits)
- MELK(7 produits)
- PDK(9 produits)
- PI3K(231 produits)
- S6 Kinase(6 produits)
- gsk-3(109 produits)
- mTOR(163 produits)
Affichez 2 plus de sous-catégories
993 produits trouvés pour "Signalisation PI3K/Akt/mTOR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-159
CAS :EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.Formule :C21H23N3O5Couleur et forme :SolidMasse moléculaire :397.424EGFR/HER2/DHFR-IN-1
Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.Formule :C14H11BrN4O2SCouleur et forme :SolidMasse moléculaire :379.23PD-M6
CAS :PD-M6 is an mTOR PROTAC degrader with a DC50 of 4.8 μM, which facilitates the ubiquitination and degradation of mTOR. It inhibits the proliferation of cancer cell lines HeLa, MCF-7, and HepG2 with IC50 values of 11.3, 2.58, and 3.23 μM, respectively, and induces autophagy. Additionally, PD-M6 specifically targets the degradation of the key protein LAMTOR1 in the mTOR signaling pathway.Formule :C30H39N9O6Couleur et forme :SolidMasse moléculaire :621.69EGFR-IN-17
EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.Formule :C27H31ClN7O3PCouleur et forme :SolidMasse moléculaire :568.01GSK3β-IN-1
CAS :GSK3β-IN-1 (compound 1) is an inhibitor of glycogen synthase kinase-3β (GSK-3β) with an IC50 value of 65 nM, and it is utilized in Alzheimer's disease research.Formule :C17H13FN2O4SCouleur et forme :SolidMasse moléculaire :360.36D-69491 hydrochloride
CAS :D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.Formule :C25H26Cl2FN7O3Couleur et forme :SolidMasse moléculaire :562.42Si306
CAS :Si306, an Src inhibitor, exhibits antitumor activity by reducing the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), thereby inhibiting the invasion of human glioblastoma (GBM).Formule :C25H26BrClN6OSCouleur et forme :SolidMasse moléculaire :573.94PI4KIIIbeta-IN-11
CAS :PI4KIIIbeta-IN-11 is a PI4KIIIβ inhibitor (mean pIC50=9.1) that can be used to study diseases caused by RNA viruses and Plasmodium falciparum.Formule :C33H39N7O3Couleur et forme :SolidMasse moléculaire :581.71Tarloxotinib bromide
CAS :Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.Formule :C24H24Br2ClN9O3Degré de pureté :99.52%Couleur et forme :SolidMasse moléculaire :681.77Ref: TM-T13088
1mg133,00€5mg268,00€10mg409,00€25mg670,00€50mg888,00€100mg1.243,00€1mL*10mM (DMSO)414,00€HER2-IN-7
CAS :HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.Formule :C28H26F3N7O3Couleur et forme :SolidMasse moléculaire :565.55PIKfyve-IN-1
PIKfyve-IN-1: potent, cell-active inhibitor for PIKfyve research, IC50=6.9 nM.Formule :C20H21N5Couleur et forme :SolidMasse moléculaire :331.41DNA-PK-IN-2
CAS :DNA-PK-IN-2 is an inhibitor of the DNA-PK enzyme complex, useful in cancer research.Formule :C20H23N5O3Couleur et forme :SolidMasse moléculaire :381.43DNA-PK-IN-15
CAS :DNA-PK-IN-15 (compound 6) acts as an inhibitor of DNA-PK, exhibiting an IC50 value of 0.08 nM.Formule :C23H23N9OCouleur et forme :SolidMasse moléculaire :441.49BML-265
CAS :BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.Formule :C18H15N3O2Couleur et forme :SolidMasse moléculaire :305.331GSK-3β inhibitor 25
CAS :GSK-3β inhibitor25 (Compound 6h) exhibits weak inhibitory activity against GSK-3β with an IC50 greater than 100 μM.Formule :C16H15NOSCouleur et forme :SolidMasse moléculaire :269.361HER2-IN-9
HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.Formule :C19H14BrF3N2OCouleur et forme :SolidMasse moléculaire :423.23EGFR-IN-139
CAS :EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).Formule :C27H25ClN2O4Couleur et forme :SolidMasse moléculaire :476.951PI4KIII β inhibitor 5
CAS :PI4KIII beta inhibitor 5 (Compound 43) is an inhibitor of PI4KIIIβ with an IC50 of 19 nM. By inhibiting the PI3K/AKT pathway, it induces apoptosis in cancer cells, causes cell cycle arrest at the G2/M phase, and promotes autophagy. Additionally, PI4KIII beta inhibitor 5 demonstrates significant anti-tumor activity in the H446 small cell lung cancer xenograft model. This compound is applicable in cancer research studies.Formule :C24H27F2N3O4S2Couleur et forme :SolidMasse moléculaire :523.616EGFR ligand-14
CAS :EGFRligand-14 serves as an EGFR ligand and is utilized in the synthesis of SJF-1521.Formule :C27H19ClFN3OCouleur et forme :SolidMasse moléculaire :455.91HER2-IN-21
CAS :HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.Formule :C20H18N4O3SCouleur et forme :SolidMasse moléculaire :394.447
